SEARCH RESULTS FOR:

Damian Chan & Cindy Koh

EXECUTIVE DIRECTOR, ENERGY & CHEMICALS AND DIRECTOR, ENERGY & CHEMICALS
Singapore Chemicals 2018
The EDB has won worldwide recognition for its continual success in fostering Singapore’s industrial and trading dominance. GBR speaks to the EDB about its activities concerning the energy and chemical industry.

Wu Yifang

CEO, FOSUN PHARMA
Fosun Pharma is a leading pharma company in China with innovative and global ambitions.

Sara Radcliffe

PRESIDENT & CEO, CALIFORNIA LIFE SCIENCES ASSOCIATION
United States Biopharmaceuticals 2018
California Life Sciences Association (CLSA) is the trade association representing California’s in-novative life sciences industry, ensuring that it retains its competitive edge.

Martin Toscano

PRESIDENT, EVONIK INDUSTRIES DE MEXICO
Mexico Petrochemicals and Chemicals 2018 APLA Pre-Release
Evonik intends to expand its operations in Mexico across the board.

K. Soner Koldas

COUNTRY DIRECTOR, PASINEX
Pasinex aims to become the biggest base metal company in Turkey.

Tobias Posel

DIRECTOR, GEOQUEST
GeoQuest has observed increased buzz in exploration in the DRC, and will re-open its presence in Zimbabwe to take advantage of projected growth there.

Dirk Lorenz-Meyer

MEMBER OF THE BOARD, BEHN MEYER
Singapore Chemicals 2018
Behn Meyer was established in Singapore in 1840 and has become a dominant force in chemical distribution across ASEAN, constantly adding new facilities and services that strengthen its offering.

Cem Yuceer

COORDINATOR, TÜMAD MADENCILIK (NUROL HOLDING)
Tümad Madencilik speaks to GBR about the development of its two producing gold mines in Turkey.

James Bannantine

CEO, GREAT PANTHER SILVER
Peru Mining 2018 Pre-Release 2
“Coricancha will provide a 75% increase in the production level for Great Panther Silver”

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS